New height growth peptide high effort high iq(manlets GTFIH)

[ragu]

So medication that i will be taking in this thread is Navepegritide it got approved by FDA this year to treat children with achondroplasia(it’s basically dwarfism) and there is some serious evidence on this drug but it’s only done on children 1-5 but there a studies going on 5-18 i think it will work its same as vosoritide
WHAT IS NAVEPEGRITIDE
Navepegritide, a prodrug of C-type natriuretic peptide, has demonstrated improved growth and additional benefits, including lower limb alignment, in children with achondroplasia. The well-described mechanism of action of navepegritide in the growth plate is hypothesized to enhance its receptivity to lonapegsomatropin, a prodrug of somatropin, to provide benefits beyond those seen with monotherapies in achondroplasia.

Research on it
Twenty-one children were enrolled: 12 received no prior growth-promoting treatment (treatment-naive, TN) and 9 had been receiving navepegritide monotherapy for >1 year (navepegritide-experienced, NE). At week 52, TN children receiving navepegritide and lonapegsomatropin had a least squares mean AGV of 8.69 cm/year versus 5.95 cm/year for matched children who received navepegritide monotherapy, a difference of 2.74 cm/year (P < .0001). Observed mean AGV for TN children was 8.80 cm/year, a +3.89 cm/year increase from baseline (P = .0015). NE children had an observed mean AGV of 8.42 cm/year, a +3.28 cm/year increase from navepegritide-treated baseline (P < .0001). An improvement in body proportionality was observed and arm span increased substantially (+9.4 cm in TN and +7.9 cm in NE children), in line with gains in height. Treatments were well-tolerated with generally mild adverse events and no treatment discontinuations.
The dosages
Navepegritide is supplied as a lyophilized powder(same as hgh you have to reconstruct it)in single‑dose vials (1.3 mg, 2.8 mg, and 5.5 mg) that require reconstitution before subcutaneous injection. It is administered once weekly with weight-based dosing per the FDA-approved prescribing information.1 The dose may be given up to two days before or after the scheduled date, ensuring at least five days between injections; if more than two days have passed, the dose should be skipped.
The sides
The most common adverse reactions (≥5%) with navepegritide 100mcg/kg/week included vomiting, transient injection‑site reactions (swelling, erythema, bruising), extremity pain, and nausea; hypertrichosis also occurred in 3% of participants.1,4,5 No treatment-related serious adverse events, such as symptomatic hypotension, fractures, or death, were reported.4 Although transient blood pressure decreases have been observed with CNP analogs, the label advises only symptom monitoring (i.e., dizziness, fatigue) and does not recommend pre-dose hydration or food intake, unlike vosoritide.1,6 Routine monitoring involves periodic assessment of growth, as well as weight-based dose adjustments. The medication should be discontinued once bone age displays epiphyseal closure. Navepegritide is not recommended for patients with moderate or severe renal impairment (eGFR <60 mL/min/1.73 m²).1
Now pricing

brutal pricing same as vosoritide but that one was at least on indiamart this shit isn’t so maybe we wait a couple years and it will appear or price will go down idk bruh
Tags
@ascendingpath

 

[ragu]

toughts boyos

 

[sh1ny_flakes431]

dnr

 

[nwed]

So medication that i will be taking in this thread is Navepegritide it got approved by FDA this year to treat children with achondroplasia(it’s basically dwarfism) and there is some serious evidence on this drug but it’s only done on children 1-5 but there a studies going on 5-18 i think it will work its same as vosoritide
WHAT IS NAVEPEGRITIDE
Navepegritide, a prodrug of C-type natriuretic peptide, has demonstrated improved growth and additional benefits, including lower limb alignment, in children with achondroplasia. The well-described mechanism of action of navepegritide in the growth plate is hypothesized to enhance its receptivity to lonapegsomatropin, a prodrug of somatropin, to provide benefits beyond those seen with monotherapies in achondroplasia.
View attachment 5578325
Research on it
Twenty-one children were enrolled: 12 received no prior growth-promoting treatment (treatment-naive, TN) and 9 had been receiving navepegritide monotherapy for >1 year (navepegritide-experienced, NE). At week 52, TN children receiving navepegritide and lonapegsomatropin had a least squares mean AGV of 8.69 cm/year versus 5.95 cm/year for matched children who received navepegritide monotherapy, a difference of 2.74 cm/year (P < .0001). Observed mean AGV for TN children was 8.80 cm/year, a +3.89 cm/year increase from baseline (P = .0015). NE children had an observed mean AGV of 8.42 cm/year, a +3.28 cm/year increase from navepegritide-treated baseline (P < .0001). An improvement in body proportionality was observed and arm span increased substantially (+9.4 cm in TN and +7.9 cm in NE children), in line with gains in height. Treatments were well-tolerated with generally mild adverse events and no treatment discontinuations.
The dosages
Navepegritide is supplied as a lyophilized powder(same as hgh you have to reconstruct it)in single‑dose vials (1.3 mg, 2.8 mg, and 5.5 mg) that require reconstitution before subcutaneous injection. It is administered once weekly with weight-based dosing per the FDA-approved prescribing information.1 The dose may be given up to two days before or after the scheduled date, ensuring at least five days between injections; if more than two days have passed, the dose should be skipped.
The sides
The most common adverse reactions (≥5%) with navepegritide 100mcg/kg/week included vomiting, transient injection‑site reactions (swelling, erythema, bruising), extremity pain, and nausea; hypertrichosis also occurred in 3% of participants.1,4,5 No treatment-related serious adverse events, such as symptomatic hypotension, fractures, or death, were reported.4 Although transient blood pressure decreases have been observed with CNP analogs, the label advises only symptom monitoring (i.e., dizziness, fatigue) and does not recommend pre-dose hydration or food intake, unlike vosoritide.1,6 Routine monitoring involves periodic assessment of growth, as well as weight-based dose adjustments. The medication should be discontinued once bone age displays epiphyseal closure. Navepegritide is not recommended for patients with moderate or severe renal impairment (eGFR <60 mL/min/1.73 m²).1
Now pricing
View attachment 5578377
brutal pricing same as vosoritide but that one was at least on indiamart this shit isn’t so maybe we wait a couple years and it will appear or price will go down idk bruh
Tags
@ascendingpath

intresting

unfortunately i dnrd a single molecule you fucking nigger

 

[ragu]

intresting

unfortunately i dnrd a single molecule you fucking nigger

Stay a manlet nigger

 

[polp]

dnr mirin efforr

 

[polp]

so what would the difference between using this and using gh in height velocity? using gh as a baseline

 

[ragu]

so what would the difference between using this and using gh in height velocity? using gh as a baseline

best is to start with gh and Aromasin and if you gp are still open take this vorositide erda

 

[polp]

best is to start with gh and Aromasin and if you gp are still open take this vorositide erda

but what would be the growth velocity difference without taking?

 

[ragu]

but what would be the growth velocity difference without taking?

what only taking hgh not this?

 

[polp]

what only taking hgh not this?

yeah, like hgh alone vs hgh plus this

 

[ragu]

yeah, like hgh alone vs hgh plus this

Okay so hgh doubles height velocity but after a year it slows down with Navepegritide after hgh if growth plates are open its a smaller but more consistent boost +1.5cm year over placebo

 

[polp]

Okay so hgh doubles height velocity but after a year it slows down with Navepegritide after hgh if growth plates are open its a smaller but more consistent boost +1.5cm year over placebo

ooh, that is nice